Monsanto, and GMO Terminator Cannabis

Now Monsanto wants to control and genetically modify your pot seeds...

Courtesy: Growth Switch Organic Blog

(WASHINGTON D.C.) - Cannabis prohibition has served to redirect human evolution from that of a decentralized agrarian lifestyle and natural economy, to a centralized petro-chemical military dictatorship controlled through the artificial economic will of private banks and other trans-national corporate interests. The next stage in continuing this control is in the regulation, licensing and taxation of Cannabis cultivation and use through the only practical means available to the corporate system, which is through genetic engineering and patenting of the Cannabis genome. Proposition 19: The Regulate, Control and Tax Cannabis Act of 2010 lays the foundation, writes RJM.

An article by D.M. Murdock written in August 2010 and entitled “Why hemp could save the world” states:

“Hemps prohibition has led to untold suffering around the globe. If we—the global human population—had been able to grow the miracle plant hemp (Cannabis genus) locally and to use it for local industries and businesses, including and especially for fuel, we would never have needed to be addicted to oil, for one, an addiction that is at the root of much misery. We would never have allowed ourselves to be lorded over by international oil-mongers whose crimes against humanity have become legion, including wholesale invasion of other lands and slaughter of countless people.”

“None of this oil-related horror—along with the deplorable degradation of the environment globally—would have occurred if hemp had not been prohibited but had been used wisely and intelligently as a major foundation of human society. Indeed, hemp-based economies could still save the human world, while hemp planting could go a massively long way in rescuing the natural world as well.”

“It is said that hemp has up to 50,000 uses, from fiber to fuel to food, but I’ll just provide a taste here:”

“In modern times, hemp has been used for industrial purposes including paper, textiles, biodegradable plastics, construction, health food, fuel, and medical purposes.”

“Hemp is one of the faster growing biomasses known, producing up to 25 tons of dry matter per hectare per year, and one of the earliest domesticated plants known. “

“One highly important use of hemp has been in detoxifying nuclear waste, as demonstrated by experiments in the Ukraine, for example, on the site of the Chernobyl nuclear disaster. Moreover, hemp fuel could actually replace the dangerous and costly nuclear power industry.”

SEE: http://www.examiner.com/freethought-in-national/why-hemp-could-save-the-world

The agenda of the government in its policies against Cannabis have always been to deprive the people access to the plant, while maintaining control over it for the government’s own self-interest. This self-interest extends to a multitude of industries including the prison and military industry, the petroleum, timber, cotton, and pharmaceutical industries, as well as the entirety of the banking and corporate establishment which has become empowered through disconnecting people from their one true source of independence and sustenance, the Earth. Cannabis prohibition has served to redirect human evolution from that of a decentralized agrarian lifestyle and natural economy, to a centralized petro-chemical military dictatorship controlled through the artificial economic will of private banks and other trans-national corporate interests.

The next stage in continuing this control, is in the regulation, licensing and taxation of Cannabis cultivation and use through the only practical means available to the corporate system, which is through genetic engineering and patenting of the Cannabis genome.

To achieve this end, the foundation is already being laid in the form of California’s upcoming initiative on the 2010 ballot. This initiative is called Proposition 19: The Regulate, Control and Tax Cannabis Act of 2010.

The leading advocate for Proposition 19 is the organization known as the Drug Policy Alliance (DPA). The DPA is the leading organization spearheading the reform of Cannabis policies in the United States, and has been made up of some of the most powerful and influential characters in today’s global petro-bio-chemical-military-banking-industrial complex.

Some of the Directors of DPA include the following:

Paul Adolph Volcker is an Honorary Director of the Drug Policy Alliance (DPA) whose career is closely associated with that of the Federal Reserve Bank. He was president of the Federal Reserve Bank of New York from 1975-1979, governing board member of the Federal Reserve in 1979, and was Chairman of the Federal Reserve from 1979-1987.

Volcker is believed to be a member of the Council on Foreign Relations, and served as Undersecretary of the Treasury from 1969-1974 before his time with the Federal Reserve. Volcker is chairman of Wolfensohn & Co. and has ties to Chase Manhattan Bank. He is also linked to the Brookings Institute, as well as being an Honorary Trustee at the Aspen Institute, chairman of the Group of 30, and on the board of the Institute for International Economics.

Frank Charles Carlucci III is an Honorary Director of the Drug Policy Alliance (DPA) and has been a member of the Council on Foreign Relations since at least 1995. His government service included positions as Deputy Secretary of Defense from 1980-1982 and Deputy Director of the CIA from 1978-1980.

Carlucci is a director on United Defense Industries (the United States’ largest defense contractor), which is owned by the Carlyle Group, a merchant bank based in Washington, D.C., of which Carlucci is the chairman. Carlucci joined Carlyle in 1989.

Before returning to Government service, Carlucci was Chairman and CEO of Sears World Trade, a business he joined in 1983. He was President Ronald Reagan’s National Security Advisor in 1987 and Secretary of Defense from 1987 to 1988.

Nicholas Katzenbach is an Honorary Director of the Drug Policy Alliance (DPA) and became General Counsel of the IBM Corporation from 1969 until 1986.

Mathilde Krim is a standing Director of the Drug Policy Alliance (DPA) and was a Trustee for the Rockefeller Foundation in 1980.

George Soros is a standing Director of the Drug Policy Alliance (DPA) and is Chairman of Soros Fund Management. Soros was among the highest paid hedge fund managers in 2009, taking home about $3.3 billion. At the end of 2009, he owned about $6.95 billion distributed among 697 stocks.

Soros’ top 5 investment shareholdings are in gold, Petrobras petroleum company, Hess Corp petroleum company, Monsanto corporation, Citigroup Inc., and Suncor Energy Inc.(petroleum company).

That’s right, George Soros, who is famous for being one of the most powerful and influential persons in world economics and whose speculations alone are said to have ‘broke the Bank of England‘, is one of the key directors for the organization that is leading the charge to regulate, control and tax Cannabis in California. All the while George Soros is one of the major shareholders in the worlds largest GM Seed bio-technology corporation known as Monsanto.

The Monsanto corporation brought you things like Agent Orange, Terminator Seeds, Monsantos Round-up ready Herbicide, and Genetically Modified and Patented Organisms made from Soybean, Corn, and Cotton to name a few. Genetically engineered crops entered the market in 1996 and to this day around 90% of all Soy, Corn, and Cotton grown in the U.S. have been Genetically Engineered and patented by a handful of bio-chemical corporations, with Monsanto owning 90% of all GMO patents.

The value of the Cannabis plant as an industry, without factoring in the value of Cannabis as a food or medicine, was estimated to be in the billions in 1938 by an article published by Popular Mechanics Magazine at that time, so its no wonder why one of Monsanto’s major shareholders would have in interest in advocating for one of the main tenants of prop 19, which is to “Make cannabis available for scientific, medical, industrial, and research purposes” and to “adopt a statewide regulatory system for a commercial cannabis industry”. Prop 19 is doing nothing less then opening the floodgates for Monsanto and other petro-chemical, GMO seed and pharmaceutical corporations to commercialize, regulate, control and tax Cannabis through genetic engineering, patenting and licensing.

Monsanto and the Drug Policy Alliance are not the only entities leading the charge to regulate Cannabis through genetic engineering. As published in the September 2009 issue of the Journal of Experimental Botany, Researchers from the College of Biological Science of the University of Minnesota have identified the genes in the Cannabis plant that produce tetra-hydro-cannabinol (THC), claiming in a press release that it is “a first step toward engineering a drug-free Cannabis plant”. George Weiblen, an associate professor of plant biology and a co-author of the study, said “Cannabis genetics can contribute to better agriculture, medicine, and drug enforcement”.

George Weiblen conducts his research under a permit granted by the DEA to import Cannabis from outside of the U.S. The two sources from which these imports come from are the Kenex corporation based in Ontario Canada and the HortaPharm corporation based in Amsterdam. These two corporations are two of the very few entities which have acquired a DEA permit to import Cannabis into the United States. The history and role of these corporations illustrate the potential of Genetic Engineering in the global Cannabis market.

Kenex corporation initiated its research program on industrial hemp in 1995 in cooperation with Ridgetown College of University of Guelph in Ontario. A research license was granted by Health Canada to proceed with the program. The scope of the project was expanded in 1996 making it the largest hemp research project in Canada.

It is interesting to note that Kenex’s research program on hemp was initiated at the University of Guelph, which is also home to 24 ag-biotech research facilities, and is heavily funded by the ag-biotech industry, including research funds from Monsanto corporation, Bayor Incorporated, Dupont, Syngenta and Dow Chemical corporation to name a few.

The University of Guelph Impact Study in 2007 states:

“Multi-national companies like Monsanto, Syngenta, Bayor Crop Science, and Semex have set up in Guelph because of the ability to closely interact with research and the ease of access to human, capital, and government resources, as well as the ability to attract investment.”

The University of Guelph has recently genetically engineered and patented the genome of a pig, which they have trademarked the EnviroPig. The University of Guelph has also recently partnered with the Monsanto corporation to genetically engineer a Glyphosate-resistant ragweed, and has contributed significant research and development into genetically engineering strains of Soybean crops. Some of the first Genetically Engineered Canadian bred Soybeans were developed at the University of Guelph, including the GMO Soybean strain called ’OAC Bayfield’. GE Soybean research at the University of Guelph has been vitally important to the growth of the GMO Soybean industry.

On January 2, 2003, the Guelph Mercury reported the following:

“Since the Canadian hemp ban was lifted in 1998, researcher Peter Dragla of the University of Guelph’s Ridgetown College has been selecting and breeding hemp plants to meet industry needs. Now, besides working on varieties with lower levels of tetra-hydro-cannabinol (THC)… he’s striving to develop hemp breeds with larger seeds.”

After Kenex corporations Hemp industry was born in a partnership with the Ridgetown college of the University of Guelph, Kenex became Canada’s largest Hemp producer and Supplies Hempseeds for food to companies like Nutiva, based in California.

One of the only other international companies which has acquired a permit to import Cannabis into the U.S. from the DEA is known as the HortaPharm R&D company based out of Amsterdam.

HortaPharm was founded in the late 1990’s by a man named David Watson.

David Watson is credited for developing some of the most widely used Cannabis strains in the world, including his famous strain called Skunk #1 which was imported and used in George Weiblens research to develop GE Cannabis strains at the University of Minnesota.

An article from: http://www.cannabisfarmer.com/web/node/39 reports the following on Mr. David Watson:

“Are your expensive Dutch female (Cannabis) seeds hard to clone, or when you try to breed them, all you get are hermaphrodites?”

“Thank Dr Frankenbeanstein, aka the Skunkman, whose real name is David Watson.”

“At a 1997 Vancouver Hemp conference, Watson spoke of his research. His main focus was to stop growers from cloning nor being able to create any seeds from strains being bred in Amsterdam. The funding for this research came partially from the Dutch Government, the rest from the DEA. Watson had been busted for growing in Santa Cruz California on March-20-1985 and resurfaced in Amsterdam to start his seed company Cultivator’s Choice. DEA supported the Watsons application for a license to grow for research in Holland, even though they should have been extraditing him back to Cali for his 1985 Santa Cruz grow bust! DEA endorsement was so strong that he was the first to be granted a permit in Holland when several universities and domestic research groups with PHD’s and legitimate reasons for research were denied! The Dutch government even supplied three greenhouses for Watson to do his heinous experiments, while normal Dutch growers lost all of their equipment and had to serve murder-like sentences at that time! Dutch seed companies have become the Monsanto of the cannabis seed industry, and hope to make us all seed junkies at $20 a seed.!”

“The license gave Watson control over what researchers are allowed access to pedigreed seeds of predictable quality! The object is to patent up every possible combination of cannabinoids with efficacy for every possible disease they can treat, and every possible genetic sequence! Once ready to make the move, they will shut down every medical cannabis grower for patent fraud”

“Monsanto terminator technology is being applied to Cannabis by (David Watson) at Hortapharm in Holland.”

SEE: http://www.cannabisfarmer.com/web/node/39

The following article published in the UK Independent on September 27, 1998, Interviewed Mr. Watson on the intent of his research in Cannabis with his company HortaPharm:

“It looks like dope, but really it’s hope,” explains David Watson. What he means is that many of these plants have been specifically bred not to produce an intoxicating resin or hashish. Indeed, HortaPharm hopes to thwart the aims of the average recreational user.”

The team is already close to finding their own commercial Holy Grail – seeds that will produce a one-off, female, seedless crop of plants with no psychotropic effects for the consumer. Why, you might ask, would they want to do that?

HortaPharm is only interested in developing female plants that are sterile, but this is not just to protect their genetic copyright. “If a plant is not kept busy producing seeds, all its energy can go into resin production,” says Watsons Dutch colleague and biochemist Etienne de Meijer.

Watson believes the bright future of (Cannabis) is contained in the greenhouses of HortaPharm and GW Pharmaceuticals.

At his Amsterdam glasshouses, he nods conspiratorially at the healthy- looking garden produce. “Don’t say anything yet, but we are also working on putting THC into tomatoes,” he confides. Then he cackles reassuringly: “Only kidding!”
SEE: http://www.independent.co.uk/news/cannabis-a-year-that-changed-minds-1200871.html

David Watson has stated “HortaPharm has built up over many years the most extensive ‘Living Library’ of Medicinal Cannabis varieties in the world”.

In July 1998, Speaking at the International Cannabinoid Research Society conference in Montpellier, Dr Geoffrey W Guy, Chairman of GW Pharmaceuticals, said that HortaPharm will provide GW with exclusive access to its entire range of cannabis varieties for the development of medicines. The worldwide rights acquired by GW for an undisclosed sum cover varieties grown to date with certain exceptions and all varieties to be bred in the future. Plant registrations arising from the Dutch breeding program will be owned by GW pharmaceutical.

Under the agreement GW Pharma will be responsible for the development of specific drug delivery technologies to administer the pharmaceutical grade medicinal cannabis. This work will include a vaporizer for which HortaPharm has a patent pending.

In addition GW Pharma will fund HortaPharm’s botanical research and HortaPharm scientists will assist in the UK Glasshouse propagation, cloning and cultivation program.

David Watson, CEO of HortaPharm has stated “As soon as Dr Guy’s clinical research indicates the exact desired composition our scientists can breed and register new medicinal varieties”.

An article published by Cannabis Culture Magazine in May 2002, states:

“GW’s miracle pot may soon be among the first cannabis plants ever patented. Although some industrial hemp genetics have been copyrighted as intellectual property, Guy is seeking to register marijuana varietals distinguished by specific morphological characteristics, such as color, leaf size and shape, and smell.”

“According to preliminary information provided exclusively to Cannabis Culture, GW’s medical devices will revolutionize the way cannabis is ingested. Cannabis extracts blended in precise ratios will be packaged in a “canister” that joins to an electromechanical device that delivers controlled aerosolized doses of plant-derived cannabinoids without delivering harmful combustion by-products.”

“The canisters and delivery devices will be dispensed by pharmacists, and closely monitored by pharmacists, doctors, and GW itself.”

”Pharmaceutical companies spend hundreds of millions of dollars researching and producing medicines, but as soon as those medicines are given to patients, they can be improperly used,” Guy explains. “Patients might use too much, too little, or they might divert their medications to other people. For medications like cannabis that are controlled substances, it’s essential that medical personnel be able to monitor dosage patterns. Our devices are like a digital camera that records details of time, date and other particulars every time it is used.”

“Physicians will be able to monitor patient usage remotely,” continued Guy. “People won’t be able to tamper with our devices, even though they are portable and easy to use. You’d need a metal saw or a blowtorch to get into one of them. These controls answer concerns of those who worry that our extracts will be used inappropriately. And, these devices can be adapted for other medicines, ensuring patient safety and medical efficacy.”

“Dr Guy and his representatives have engaged in high level discussions with the DEA, FDA, the Office for National Drug Control Policy (ONDCP), National Institute for Drug Abuse (NIDA) and senior state officials in California and Maine.”

“We’ve made some progress in the US,” Guy says. “We’ve commenced pre-clinical research in laboratories and other research in a university. This research is aimed at cell protection properties, general pharmacology, and the enhancement of effects afforded by beneficial synergy created when cannabinoids are blended together rather than isolated. The DEA has approved importation of our extracts into the US. They haven’t said no to us on anything we’ve asked so far. They are playing it by the book. We look forward to continued progress.”

“GW occupies a lead position world-wide,” concludes Guy. “We are uniquely placed to become the first company to achieve regulatory approval for prescription cannabis-based medicines.”“
SEE: http://www.cannabisculture.com/v2/articles/2400.html

In an interview with Cannabis Culture Magazine, the Chairman of GW Pharma Dr. Geoffrey Guy said “We deserve to make a fair return on our investment, and that’s why we pursued patents for our plants, extracts, processes, and delivery devices.”

In 2009 in Canada, GW Pharma has succeeded in “artificially manipulating” and Patenting a “Novel Reference Cannabis Plant” with a “knock out gene” that uses “monogenic mutation” to “block the cannabinoid biosynthesis in Cannabis sativa”. This technology is being used to artificially engineer the levels of medicinal compounds in the plant.
SEE: http://www.faqs.org/patents/app/20090035396

You want to keep reading, click this link for the conclusion of Monsanto, and GMO Terminator Cannabis Monsanto, and GMO Terminator Cannabis - Growth Switch Organic Blog

Salem-News.com Marijuana Coverage

Where and How to Smoke Legal Marijuana without Fear of Arrest in the U.S.

Eulogy of a Great Warrior: Hoss Plourde

The Ripple Effect How Marijuana Laws Are Impacting Society

Audit the Audit

Welcome Home, Tom

Comments Leave a comment on this story.

Name:

All comments and messages are approved by people and self promotional links or unacceptable comments are denied.

---

Wow August 20, 2011 5:07 pm (Pacific time)

Ignorant and short on facts. There's a difference between things Monsanto does and companies they bought up that hold patents on things. Also, this article is a collection of dead and somewhat suspect information that's been around on the internet for a long time.

Enjoy your fear, everyone.

Editor: We weren't just born yesterday, I personally have been on this trail for over two decades and our other writers much longer.  Trust me, the fear is real and justified and nobody is enjoying it.

[Return to Top]

---

©2024 Salem-News.com. All opinions expressed in this article are those of the author and do not necessarily reflect those of Salem-News.com.